Access to healthcare is a human right. LABDX ASIA Holdings through its subsidiary LABX Corp has designed and developed a next generation telemedicine platform branded as LIFE. A bio-medical technology that empowers humanity. Through its advocacy ONE PINOY : ONE NURSE it aims to provide a national primary care- network for all provinces, cities of the Philippines and rest of world. Where every patient has access to a nurse who then navigates all to a digital health village of medical specialists and healthcare facilities for immediate care. The service also provides tele-diagnostics via LIFE point of care medical tools that allow all to remotely diagnosis at the comfort of one’s home, school or office assisted by LIFE’s tele-testing nurses.
What we do
TELETESTING
LIFE SCIENCE EQUIPMENTS
DIAGNOSTICS
TELEMEDICINE
MEDICAL RECORDS
PHARMA
making healthcare a utility
LIFE
A complete Telemedicine service developed by LABX that integrates AI, Health care professionals, EMR, connectivity ( video/text/voice). Where nurses are at the forefront of navigating , reminding, referring and hand holding each and every patient. Providing local and global primary care.
TELETESTING
A ubiquitous GLOBAL telemedicine service provided by a registered healthcare professional
(Registered Nurse) and in-home diagnostic test kits (platform).
Why we are different
LABx provides diagnostic services for people who need them the most, and where it matters the most: their homes and the places they personally frequent. This is in line with our mission of bringing accessible, affordable, and accurate testing to everyone.
our products
LABx Corp. specializes in cutting-edge diagnostics with a focus on testing for the SARS-CoV-2 virus. Through our extensive array of equipment approved by regulatory boards across the globe, LABx aims to provide next-level solutions in the field of COVID-19 testing.
LABX SPIN CM4 & CM5
Centrifugal microfluidic biochemical POCT test platform
- Xenon light source
- Microfluidic Reagent Rotor 7 minutes Sample-to-answer in 3 simple steps and approximately 7 minutes
- Serve on the Space Station since April 2021
- Varieties of lyophilized dish packages, suitable for personalized medical treatment
- Instrument miniaturization, lyophilized reagent pre-packaged design,
- convenient transportation
- Quick detection, easy to operate
- Whole blood detection, standard addition
- Preinstalled reagent discs deliver complete results in nearly 10 minutes for each run
- Very small sample needed-only 100 microliters of whole blood, serum or plasma to get up to 15 parameters
- Factory-calibrated information in QR code
ARIA
Qualitative Antigen Rapid Immunoassay and visual read test
ARIA ( antigen rapid immune assay ) Home use/self test that is Affordable, Accurate, accessible & backed by the most advanced digital medical platforms.
A simple Swab – DROP – wait 3 easy steps to test yourself. And, you can scan for a nurse using our teletest service ( MEDX) where an English speaking nurse ( other languages available) virtually & face to face administers the simple steps and provides interpretation of results. This is required for medical certification and in regulated markets.
The Aria is integrated with Symptoma the only Artificial intelligent digital health assistant that has been awarded a Medical device Type authorization. www.symptoma.com
Regulatory approvals include the EU , PH and many other nations.
FINA Ag
Quantitative antigen testing for initial diagnosis
FINA Ag is a dry fluorescence immunoassay (FIA) quantitative antigen screen test which can detect the viral presence of SARS-CoV-2 via a painless nasal swab that only takes 15 minutes. It has a sensitivity rating of 100% and a specificity rating of 100%. FINA Ag is our most affordable SARS-CoV-2 viral test by far, and it is known to be highly accurate, accessible (available at point-of-care), and affordable. Call us for special introductory pricing.
WHERE WE ARE GOING
LABX SEEKS TO PROVIDE NEXT-GENERATION DIAGNOSTICS THAT ARE
AFFORDABLE, ACCURATE, AND ACCESSIBLE.
To achieve this, it has partnered with the top biomedical, genetic engineering, and diagnostic institutions—both commercial and research-driven ones—across the globe. Furthermore, it continues to invest and roll out new testing options that ultimately empower the patient.
LABX AIMS TO DECENTRALIZE DIAGNOSTICS AWAY FROM USUAL HUBS LIKE HOSPITALS.
In line with this, it plans to bring point-of-care testing capabilities closer to homes and other
similarly accessible milieus.
LABX’S GOAL IS TO MAKE HEALTHCARE A UTILITY THAT IS WITHIN REACH OF EVERYONE.
Towards the goal of allowing families and workers to diagnose themselves at the comfort of their workplace, school, or home, LABx is set to unveil LABx Dx, which is coming very soon.
